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Article: Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients 
with gastroparesis
(J Neurogastroenterol Motil 2010;16:407-413)
Gastroparesis is a syndrome characterized by symptomatic 
impairment of transit of foods from stomach to the duodenum in 
absence of mechanical obstruction.
1 Though gastroparesis is 
thought to be an uncommon disorder, many patients with this 
disease are diagnosed and managed as dyspepsia;
2 hence, this 
condition is likely to be under-diagnosed. Gastroparesis may be 
caused by diabetes mellitus, systemic viral infection,
3 hypo and 
hyperthyroidism, hypo and hyperparathyroidism, Addison’s dis-
ease, collagen vascular diseases, amyloidosis, malignancies,
4,5 gas-
tric surgery, parkinsonism, other neurodegenerative diseases and 
myopathies.
1 In a proportion of patients with gastroparesis, no 
etiology can be found. Gastroparesis affects about 20%-30% of 
the patients with diabetes mellitus,
6 which is common and is in-
creasing all over the world. Symptoms of gastroparesis include 
nausea, vomiting, early satiety, postprandial bloating and ab-
dominal pain.
1,7 In a series of 146 patients with gastroparesis, fre-
quency of nausea, vomiting, abdominal bloating and early satiety 
was reported by 92%, 84%, 75% and 60%, respectively.
7 The ma-
jor goals while treating a patient with gastroparesis include, (1) 
relieving symptoms particularly vomiting, (2) maintenance of nu-
trition and (3) finding and treating the cause, which may be the 
only potential curative treatment.
D i e t  t h a t  p r o l o n g s  g a s t r i c  e m p t y i n g  s h o u l d  b e  a v o i d e d .  
These include diet rich in fat and fiber.
8 If patient is on drugs that 
may prolong gastric emptying, such drugs should be stopped. 
Though solid emptying from the stomach is prolonged in pa-
tients with gastroparesis, liquid emptying is either normal or fast-
er in most. Hence, diet should be liquid or semisolid. Small fre-
quent meals may help the patients. Prokinetics are the mainstay in 
treatment of gastroparesis. These include metoclopramide, dom-
peridone, itopride, levosulpiride, cintapride, mosapride, tegaser-
od and macrolide antibiotics such as erythromycin.
8,9 In refrac-
tory patients, prokinetics with different mechanism of action may 
be combined. In patients refractory to drug treatment, endo-
scopic intra-pyloric injection of botulinum toxin may be useful.
10 
Gastric pacemaker is useful in refractory gastroparesis.
11 Surgery 
is reserved as a last resort in treatment of gastroparesis.
12 If modi-
fied diet can not be tolerated by the patients, parenteral nutrition 
may be required.
12 If a specific cause, such as diabetes mellitus or 
hypothyroidism is detected, treatment directed against this cause Pharmacotherapy for Gastroparesis
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may lead to recovery from gastroparesis.
Among the prokinetics, which are the first-line treatment of 
gastroparesis, cisapride has been withdrawn from the market due 
to its potential for causing QT prolongation and cardiac arrhy-
thmias.
13 The pro-motilin macrolide antibiotic erythromycin, ac-
celerates gastric emptying by inducing antral contractions and 
improved gastroduodenal coordination.
14 It is quite popular in 
treatment of gastroparesis in United States of America. How-
ever, like cisapride, it has cardiac side-effect such as QT pro-
longation and may result in potentially fatal cardiac arrhy-
thmias.
15 Furthermore, gastrointestinal side effects such as nau-
sea and diarrhea are common with erythromycin.
16 Erythromycin 
has limitations due to its marked ability to inhibit cytochrome 
P450 resulting in interaction with drugs, which are metabolized 
by this enzyme system such as warfarin, carbamazepine and theo-
phylline etc.
16 Concern about development of microbial resist-
ance to this antibiotic following its use as pro-motility agent is also 
a growing issue. Hence, attempt to evaluate a safer alternative to 
erythromycin in treatment of gastroparesis is welcome.
In this issue of the journal, Moshiree et al evaluated whether 
azithromycin can serve as a safer alternative to erythromycin to 
promote gastric emptying in patients with gastroparesis. The 
same group of authors in an earlier study on 30 patients with gas-
troparesis showed that intravenous erythromycin 250 mg and azi-
thromycin at similar doses showed a similar positive effect on an-
tral activity. However, comparison of erythromycin and azi-
thromycin at the higher dose of 500 mg showed that the mean 
amplitude, duration of antral activity and motility index were sig-
nificantly higher with azithromycin.
17 Recently, another group of 
workers reported a patient with refractory diabetic gastroparesis 
responding to high dose (500 mg/day) intravenous azithromy-
cin.
18 The present study found that gastric emptying was equally 
hastened by azithromycin and erythromycin. Both the drugs were 
found safe during the study period. Hence, authors concluded 
that azithromycin was equivalent to erythromycin in accelerating 
gastric emptying in adult patients with gastroparesis. They sug-
gested that longer duration of action, better side effect profile, 
and lack of P450 interaction of azithromycin as compared with 
erythromycin may favor azithromycin over erythromycin.
Though such conclusions are quite thought-provoking, the 
authors correctly suggested the need for more studies. In fact, the 
present study raises more questions than answers. The issues, 
which can be raised in the present study include small sample size 
resulting in a possibility of type II statistical error, non-random-
ized design, lack of a placebo arm and a short observation period. 
Gastroparesis is a chronic disease requiring long-term therapy; 
hence, a study evaluating short-term effect of a parenteral drug 
for a chronic disease may not be clinically meaningful. The issue 
of tachyphylaxis during long-term use of the drug also needs to 
be addressed. The concern of development of microbial resist-
ance to erythromycin remains with azithromycin as well. Though 
safety was considered to be a major advantage of azithromycin 
over erythromycin, this could not be substantiated by the data as a 
single dose of each drug was used and hence, no side effect was 
reported with either drug. It is important to note that side-effects 
are not uncommon on long-term use of macrolide antibiotics 
such as erythromycin or azithromycin; as high as 28% patients on 
erythromycin and 9% on azithromycin experience gastrointes-
tinal side effects such as nausea and diarrhea.
16 Moreover, it is 
important to know whether improvement in gastric emptying fol-
lowing azithromycin would translate into improvement in symp-
toms. In an earlier study, though erythromycin improved gastric 
emptying, such improvement was not associated with a beneficial 
effect on meal related symptom severity.
19
In spite of all the limitations of the study mentioned above, it 
is an important step to find out a safer alternative to pharmaco-
therapy of gastroparesis as “A journey of a thousand miles begins 
with a small step” Lao Tzu, Chinese Founder of Taoism (570- 
490 BC).
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